Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Conference News
Plain English
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Annotation

Coyle JT. Nitric oxide and symptom reduction in schizophrenia. JAMA Psychiatry . 2013 Jul 1 ; 70(7):664-5. PubMed Abstract

Comments on Paper and Primary News
Primary News: Sodium Nitroprusside Rapidly Quells Schizophrenia Symptoms

Comment by:  Philip Seeman (Disclosure)
Submitted 15 May 2013 Posted 15 May 2013

Hopefully, this apparent antipsychotic action of nitroprusside can be replicated. In the meantime, it should be noted that their background work on animals found that nitroprusside inhibited the action of phencyclidine, thought to act on NMDA receptors. Phencyclidine, however, has a higher affinity for the dopamine D2 receptor (with dissociation constant of 4 nM at the D2High receptor) compared to the ionotropic glutamate receptor (with dissociation constant of between 100 nM and 2,000 nM) (Seeman and Guan, 2008).

More importantly, Giannini et al. (1984, 1984-1985) showed that phencyclidine was selectively blocked in emergency room subjects by haloperidol, which has selective D2 blocking action but no action on NMDA transmission. Therefore, should nitroprusside and related drugs (amyl nitrate, nitroglycerin) have antipsychotic action, the potencies of these drugs on dopamine transmission will need to be examined.

References:

Giannini AJ, Eighan MS, Loiselle RH, Giannini MC. 1984. Comparison of haloperidol and chlorpromazine in the treatment of phencyclidine psychosis. J Clin Pharmacol 24:202-204. Abstract

Giannini AJ, Nageotte C, Loiselle RH, Malone DA, Price WA. 1984-85. Comparison of chlorpromazine, haloperidol and pimozide in the treatment of phencyclidine psychosis: DA-2 receptor specificity. Clin Tox 22(6):573-579. Abstract

Seeman P, Guan H-C. Phencyclidine and glutamate agonist LY379268 stimulate dopamine D2High receptors: D2 basis for schizophrenia. Synapse 62: 819-828 (2008). Abstract

View all comments by Philip Seeman


Primary News: Sodium Nitroprusside Rapidly Quells Schizophrenia Symptoms

Comment by:  Leslie Citrome
Submitted 10 June 2013 Posted 10 June 2013

The authors report on a double-blind, randomized, placebo-controlled study of 20 persons with schizophrenia early on in their disease course. After a single infusion of sodium nitroprusside, a rapid improvement of symptoms was observed, with evidence suggesting a persistence of effect for four weeks after drug administration. This treatment was adjunctive to antipsychotics, mostly dosed in the low range, but there were subjects receiving relatively high doses, suggesting they were not easy to treat. Patients on clozapine were excluded. The use of lithium, antidepressants, or anticonvulsant medications was not described, nor was the use of PRN medication for sleep, anxiety, or agitation.

The authors do acknowledge that further studies are required. The accompanying editorial by Dr. Coyle notes "the field is littered with small trials with robust outcomes that ultimately are not replicated." In addition to supporting a claim for efficacy, larger trials are required to establish safety.

Although the use of intravenous agents to quell the symptoms of...  Read more


View all comments by Leslie Citrome
Submit a Comment on this Paper
Make a comment on this paper. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Affiliation  
Country or Territory  
*Login Email Address  
*Confirm Email Address  
*Password  
*Confirm Password  
Remember my Login and Password?  
Get SRF newsletter with recent commentary?  
 
Enter the code as it is shown below:
This code helps prevent automated registrations.

I recommend this paper

Please note: A member needs to be both registered and logged in to submit a comment.

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


 
 
SRF News
SRF Comments
Text Size
Reset Text Size
Email this pageEmail this page

Share/Bookmark
 
Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright